BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 10638413)

  • 1. Fluorine-18 fluorodeoxyglucose dual-head positron emission tomography in the detection of recurrent differentiated thyroid cancer: preliminary results.
    Stokkel MP; de Klerk JH; Zelissen PM; Koppeschaar HP; van Rijk PP
    Eur J Nucl Med; 1999 Dec; 26(12):1606-9. PubMed ID: 10638413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-FDG-PET in the follow-up of thyroid cancer.
    Lind P; Kresnik E; Kumnig G; Gallowitsch HJ; Igerc I; Matschnig S; Gomez I
    Acta Med Austriaca; 2003; 30(1):17-21. PubMed ID: 12558561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
    Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
    Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer.
    Dietlein M; Scheidhauer K; Voth E; Theissen P; Schicha H
    Eur J Nucl Med; 1997 Nov; 24(11):1342-8. PubMed ID: 9371865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer.
    Nascimento C; Borget I; Al Ghuzlan A; Deandreis D; Hartl D; Lumbroso J; Berdelou A; Lepoutre-Lussey C; Mirghani H; Baudin E; Schlumberger M; Leboulleux S
    Thyroid; 2015 Apr; 25(4):437-44. PubMed ID: 25633259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
    Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of fluorodeoxyglucose-PET in patients with differentiated thyroid carcinoma.
    Zuijdwijk MD; Vogel WV; Corstens FH; Oyen WJ
    Nucl Med Commun; 2008 Jul; 29(7):636-41. PubMed ID: 18528186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The usefulness of fluorine-18 fluorodeoxyglucose PET in the detection of recurrence in patients with differentiated thyroid cancer with elevated thyroglobulin and negative radioiodine whole-body scan.
    Stangierski A; Kaznowski J; Wolinski K; Jodlowska E; Michaliszyn P; Kubiak K; Czepczynski R; Ruchala M
    Nucl Med Commun; 2016 Sep; 37(9):935-8. PubMed ID: 27383190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data.
    Vural GU; Akkas BE; Ercakmak N; Basu S; Alavi A
    Clin Nucl Med; 2012 Oct; 37(10):953-9. PubMed ID: 22899202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postradioiodine treatment whole-body scan in the era of 18-fluorodeoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels.
    Leboulleux S; El Bez I; Borget I; Elleuch M; Déandreis D; Al Ghuzlan A; Chougnet C; Bidault F; Mirghani H; Lumbroso J; Hartl D; Baudin E; Schlumberger M
    Thyroid; 2012 Aug; 22(8):832-8. PubMed ID: 22853728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131I whole-body scan results.
    Ozkan E; Aras G; Kucuk NO
    Clin Nucl Med; 2013 May; 38(5):326-31. PubMed ID: 23486319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
    Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
    Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
    Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal threshold of stimulated serum thyroglobulin level for
    Chai H; Zhang H; Yu YL; Gao YC
    J Huazhong Univ Sci Technolog Med Sci; 2017 Jun; 37(3):429-432. PubMed ID: 28585147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and pathological factors related to 18F-FDG-PET positivity in the diagnosis of recurrence and/or metastasis in patients with differentiated thyroid cancer.
    Esteva D; Muros MA; Llamas-Elvira JM; Jiménez Alonso J; Villar JM; López de la Torre M; Muros T
    Ann Surg Oncol; 2009 Jul; 16(7):2006-13. PubMed ID: 19415387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of the negative PET-FDG in the middle term follow-up of differentiated thyroid cancer in patients with negative 131 I-Na scan and elevated thyroglobulin serum levels.
    Pachón-Garrudo VM; Cuenca-Cuenca JI; Ruiz-Franco-Baux J; Borrego-Dorado I; Tirado-Hospital JL; Navarro-González E; Vázquez-Albertino R
    Rev Esp Med Nucl Imagen Mol; 2012; 31(6):315-21. PubMed ID: 23084014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer.
    de Geus-Oei LF; Oei HY; Hennemann G; Krenning EP
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer.
    Iwata M; Kasagi K; Misaki T; Matsumoto K; Iida Y; Ishimori T; Nakamoto Y; Higashi T; Saga T; Konishi J
    Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):491-8. PubMed ID: 14666387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131)I whole body scan: evaluation by thyroglobulin level.
    Na SJ; Yoo IeR; O JH; Lin C; Lin Q; Kim SH; Chung SK
    Ann Nucl Med; 2012 Jan; 26(1):26-34. PubMed ID: 21971605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer.
    Shammas A; Degirmenci B; Mountz JM; McCook BM; Branstetter B; Bencherif B; Joyce JM; Carty SE; Kuffner HA; Avril N
    J Nucl Med; 2007 Feb; 48(2):221-6. PubMed ID: 17268018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.